Tumor Profiling: From Complexity to Clarity

Every tumor represents a complex ecosystem comprising diverse genetic mutations, cellular subpopulations, and dynamic interactions within the tumor microenvironment (TME).¹ Researchers require precise tools to profile these complexities, identify therapeutic targets, and develop innovative treatments.

Empower your research with a comprehensive suite of technologies that:

• Accelerate discovery in novel research areas
• Streamline workflows to improve efficiency
• Maximize data output from precious samples
• Generate reproducible results across multi-site research initiatives

Start a Conversation with a Specialist

Multi-dimensional tumor profiling relies on analyzing multiple biomarkers to build a comprehensive view of disease state and progression. Researchers need highly precise tools to explore evolving genetic targets and extract meaningful insights from complex tumor biology.

Traditional real-time PCR (qPCR) methods reliably measure gene expression changes of two-fold or greater. At the same time, Droplet Digital™ PCR (ddPCR™) allows visualization of changes of less than two-fold and facilitates the ease of multiplexing. Additionally, ddPCR solutions offer same-day workflows and exceptional precision, ideal for formalin-fixed paraffin-embedded (FFPE) and liquid biopsy samples.

Our high resolution genomics solutions help you accurately detect low-abundance targets, perform rapid serial analyses, and accelerate biomarker discovery, allowing you to maximize sample value and advance targeted therapy development.

Droplet Digital™ PCR (ddPCR)

Accelerate translational research with advanced assay multiplexing to detect and quantify rare, low-abundance targets like EGFR, T790M, L858R, and KRAS G12C with industry-leading sensitivity.

PrimePCR Assays on ddPCR

Precisely quantify single mutations to identify actionable targets, accelerate decisions, reduce time-to-results, and advance therapeutic development.

PrimePCR™ Panels

Streamline detection of cancer-relevant regulators with pre-designed qPCR gene expression panels, ensuring reliable, pinpoint data acquisition for meaninful insights and efficient workflows.

QX Manager ddPCR Software

Enhance your ddPCR workflow with QX Manager. Gain precise process control, reduce variability, and generate reproducible results that guide therapeutic decisions and improve research efficiency.

Image

Disease Monitoring with Liquid Biopsy and ddPCR

Liquid biopsy with ddPCR provides real-time insight into cancer progression, recurrence, or remission. This low-risk solution eliminates the delays of tissue sampling and delivers faster, more actionable results for your research.

Unravel the complexities of the TME, a key driver of cancer progression,³ with biomarker analysis and cytokine detection solutions for tumor profiling. Discover the pathways responsible for therapeutic resistance and get one step closer to your next big breakthrough.

Image

Bio-Plex® Multiplex Assays

Quantify cytokines, chemokines, and growth factors such as IFN-γ, IL-2, IL10, CCL2, CCL5, TGF-β, and VEGF, providing insight into disease development and progression, potential metastasis, and response to treatment.

Image

ZE5 Cell Analyzer

Automate multi-parameter flow cytometry to analyze immune and tumor cell interactions with exceptional speed and sensitivity for rare event detection. With superior fluidics and sample handling ideal for solid tumor analysis.

Image

Flow cytometry, antibodies, and StarBright™ Dyes

Get consistent, reproducible results when identifying key immune cell populations and their functional states with highly cited antibodies. Build better panels with StarBright Dyes.

Conserve valuable samples, such as those from preclinical or clinical research, while obtaining robust, high-quality data to inform critical decisions. Bio-Plex Multiplex Immunoassays maximize the efficiency of your research by simultaneously measuring up to 48 targets for immune biomarker analysis from a single, minimal sample.

Explore More Bio-Plex Solutions

Image

Empower your Cancer Research with Bio-Plex Multiplex Cytokine Assays

Learn how Dr. Hunseok Lee accelerated vaccine and cancer drug development with the Bio-Plex system by analyzing up to 17 cytokines simultaneously. This high-efficiency approach minimized sample waste, cut costs, and delivered rapid, multi-target results to drive his team’s breakthrough discoveries.

Image

Advancing Oncology Research with xMAP-Based Bio-Plex Multiplex Immunoassays

Discover how Bio-Plex Multiplex Immunoassays enable high throughput immune biomarker analysis, empowering oncology researchers to profile the immune landscape of cancer more comprehensively, aiding in the prediction of immunotherapy response, surveillance of the tumor microenvironment, and identification of biomarkers of adverse immune reactions.⁴

Explore the ddPCR Publication Database

References

¹ Zahir, N., Sun, R., Gallahan, D. et al. Characterizing the ecological and evolutionary dynamics of cancer. Nat Genet 52, 759–767 (2020).
² Chakraborty, S., Hosen, M. I., Ahmed, M., & Shekhar, H. U. (2018). Onco‐multi‐OMICS approach: a new frontier in cancer research. BioMed research international, 2018(1), 9836256.
³ Hinshaw, Dominique C., and Lalita A. Shevde. "The tumor microenvironment innately modulates cancer progression." Cancer research 79.18 (2019).
⁴ Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024). Targeting cytokine and chemokine signaling pathways for cancer therapy. Signal transduction and targeted therapy, 9(1), 176.